EC approves BMY's Breyanzi for relapsed or refractory FL, based on Phase 2 study showing high response rates & sustained ...

The Foreign Office today informed anyone travelling to 29 European countries that the EU is planning a major change towards ...

The EC has granted expanded approval to BMS' Breyanzi, to treat adults with relapsed or refractory follicular lymphoma (FL).

Etex Group has unveiled its largest-ever investment with the opening of a new plasterboard manufacturing facility in Bristol.

Bristol Myers Squibb has won European Commission expanded approval of its CAR-T cell therapy Breyanzi in the blood cancer lymphoma.

Princeton: Bristol Myers Squibb has announced that the European Commission (EC) has granted approval to Breyanzi ...

Investing.com -- The European Commission has granted Bristol Myers (NYSE: BMY) Squibb, the biopharmaceutical company based in ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

A new report has revealed how the 100 most populated cities globally are becoming increasingly exposed to flooding and ...